Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,600
Employees17,600
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,600
Employees17,600

GILD Key Statistics

Market cap
138.66B
Market cap138.66B
Price-Earnings ratio
23.57
Price-Earnings ratio23.57
Dividend yield
2.78%
Dividend yield2.78%
Average volume
5.98M
Average volume5.98M
High today
$111.49
High today$111.49
Low today
$108.73
Low today$108.73
Open price
$111.03
Open price$111.03
Volume
4.93M
Volume4.93M
52 Week high
$119.96
52 Week high$119.96
52 Week low
$70.21
52 Week low$70.21

GILD News

Seeking Alpha 3h
Gilead reaches $202M settlement over HIV drug speaker program

Gilead Sciences (NASDAQ:GILD) has reached a $202M deal with a group of attorneys general in the U.S. to settle allegations that its promotional speaker programs...

Gilead reaches $202M settlement over HIV drug speaker program
TipRanks 1d
Gilead Sciences and Arcus Biosciences: New Lung Cancer Treatment Combinations Under Evaluation

Gilead Sciences ((GILD)), Arcus Biosciences ((RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Elevate Your Invest...

TipRanks 4d
Gilead estimates Q2 acquired IPR&D expenses of $61M

For the second quarter of 2025, Gilead (GILD) currently expects $61M in acquired IPR&D expenses, representing a charge of roughly 4c to both GAAP and non-GAAP e...

Analyst ratings

62%

of 29 ratings
Buy
62.1%
Hold
37.9%
Sell
0%

More GILD News

TipRanks 5d
Gilead Sciences’ New HIV Treatment Study: A Potential Game Changer?

Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advan...

Simply Wall St 6d
Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug

recently announced a partnership with the Global Fund to supply lenacapavir for HIV prevention, marking a significant client collaboration. This and other posit...

Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug
Benzinga 6d
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million

Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenac...

Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million
Benzinga 6d
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'

In a rapidly evolving financial landscape, insights from top investment strategists and analysts can significantly influence market sentiment and investment str...

Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.
Vertex Pharmaceuticals
VeriSign
Spotify
Exelixis
United Therapeutics
Sprouts Farmers Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.